PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 19.11.2019 at 4:00 PM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2014173886) ANTI-CANCER TREATMENTS WITH ANTI-EGFR ANTIBODIES HAVING A LOW FUCOSYLATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2014/173886 International Application No.: PCT/EP2014/058118
Publication Date: 30.10.2014 International Filing Date: 22.04.2014
IPC:
C07K 16/28 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
GLYCOTOPE GMBH [DE/DE]; Robert-Rössle-Straße 10 13125 Berlin, DE
Inventors:
GOLETZ, Steffen; DE
DANIELCZYK, Antje; DE
Agent:
ROTH, Carla; Mönchenwerther Straße 11 40545 Düsseldorf, DE
Priority Data:
13002106.622.04.2013EP
13002108.222.04.2013EP
Title (EN) ANTI-CANCER TREATMENTS WITH ANTI-EGFR ANTIBODIES HAVING A LOW FUCOSYLATION
(FR) TRAITEMENTS ANTICANCÉREUX COMPRENANT DES ANTICORPS ANTI-EGFR PRÉSENTANT UNE FAIBLE FUCOSYLATION
Abstract:
(EN) The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-EGFR antibodies having improved glycosylation characteristics, in particular a reduced fucosylation, is provided which show anti-cancer efficacy and an improved adverse side effect profile.
(FR) La présente invention concerne le domaine de la thérapie anticancéreuse utilisant des anticorps anticancéreux. L'utilisation médicale des anticorps anti-EGFR présentant des caractéristiques améliorées de glycosylation, en particulier une fucosylation réduite, est décrite, lesquels anticorps démontrant une efficacité anticancéreuse et un profil amélioré d'effets secondaires indésirables.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA2908819SG11201507743XKR1020150144804CN105229030EP2989126US20160068609
IL242071JP2016516800EA201591977NZ712218AU2014257650ID2017/04899
IN7112/CHENP/2015BR112015025955